A Phase 2 interventional study of SHR-1139 Injection and SHR-1139 Injection Placebo in Palmoplantar Pustulosis of Adults, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
The study is being conducted to evaluate the efficacy and safety of SHR-1139 injection.
Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-1139 Injection
Drug: SHR-1139 Injection
SHR-1139 Injection Placebo.
Drug: SHR-1139 Injection Placebo
SHR-1139 Injection.
SHR-1139 Injection Placebo.
Change from baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI)
Absolute change from baseline in PPPASI score.
Time frame: Baseline to Day 113.
Proportion of participants achieving at least 50% improvement from baseline in PPPASI (PPPASI 50) by Day 449
Proportion of participants who achieve PPPASI 50 response.
Time frame: Baseline to Day 449.
Proportion of participants achieving at least 75% improvement from baseline in PPPASI (PPPASI 75) by Day 449
Proportion of participants who achieve PPPASI 75 response.
Time frame: Baseline to Day 449.
Proportion of participants achieving Palmoplantar Pustulosis Physician's Global Assessment (PPPGA) score of 0 or 1 (PPPGA 0/1) by Day 449
Proportion of participants who achieve PPPGA 0/1 response.
Time frame: Baseline to Day 449.
Proportion of participants achieving Dermatology Life Quality Index (DLQI) score of 0 or 1 by Day 449
Proportion of participants who achieve DLQI 0/1 response.
Time frame: Baseline to Day 449.
Change from baseline and percentage change from baseline in Psoriasis Area and Severity Index (PASI) score among participants with baseline BSA ≥ 3%, within 449 days
Absolute and percent change from baseline in PASI.
Time frame: Baseline to Day 449.
Proportion of participants achieving PASI 75, PASI 90, and PASI 100 among those with baseline BSA ≥ 3%, within 449 days
Proportion of participants who achieve PASI 75/90/100 response.
Time frame: Baseline to Day 449.
Proportion of participants achieving PPPGA 0 by Day 449
Proportion of participants who achieve PPPGA 0 (clear).
Time frame: Baseline to Day 449.
Change from baseline and percentage change from baseline in DLQI by Day 449
Absolute and percent change from baseline in DLQI.
Time frame: Baseline to Day 449.
Safety and tolerability within 449 days: adverse events (AEs)
AEs assessed by vital signs, lab tests, and ECG.
Time frame: Baseline to Day 449.
Pharmacokinetics (PK) within 449 days: serum concentration of SHR-1139
Serum concentration of SHR-1139 over time.
Time frame: Baseline to Day 449.
Immunogenicity within 449 days: incidence and time of occurrence of positive anti-drug antibodies (ADA)
ADA incidence and onset time.
Time frame: Baseline to Day 449.
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1139
Guangdong Hengrui Pharmaceutical Co., Ltd →